An encouraging example comes from the selective inhibition of HDAC6 by tubastatin A, ACY‐1215 (ricolinostat), MPT0G211 or 5‐aroylindoles, which have shown promising results in AD animal models (Fan et al., 2018; Lee et al., 2018; Onishi et al., 2021) and are currently under clinical trial evaluation for diseases other than neurodegeneration. This evidence concerns the gene HDAC6 and Alzheimer disease.